Funding available for research projects with commercialization potential
CTSI’s Office of Discovery and Translation (ODAT) issues the 7th Translational Product Development Fund (TPDF) RFA funding cycle to support projects that advance research discoveries towards commercializable products.
University of Minnesota and Mayo Clinic investigators with projects focused on product development and the intention to form a start-up company or execute a license agreement with an established commercial entity are eligible to apply for funding.
The TPDF program was established in 2014 by CTSI, the Mayo Clinic Center for Clinical and Translational Science (CCaTS) and the Minnesota Partnership for Biotechnology and Medical Genomics to develop and commercialize innovative therapies and treatment approaches to improve human health.
“Since 2015, the TPDF program has supported several projects through their translational journey with highly successful outcomes, including start-up formation and acquisition, execution of license agreements, and advancement towards clinical trials.” said Tucker LeBien, PhD, Director of CTSI’s Office of Discovery and Translation, Senior Advisor for Research Operations, Office of Academic Clinical Affairs.
Projects that include development of novel therapeutic compounds, devices, diagnostics, or IT products, are eligible to apply for Tier 1 funding of up to $50,000 in direct costs and project support with the goal of continuing translational development. Projects meeting initial milestones during Tier 1 funding will be eligible to apply for additional Tier 2 funding through this program.
The program is open to all full-time University of Minnesota faculty at all campuses, and Mayo Clinic Associate Consultant to Consultant investigators from Mayo's Rochester campus. Joint projects between the two institutions are welcome, but not required.
Mandatory letters of intent are due 5pm, Wednesday, February 5 via an online form on CTSI’s website. Projects will be evaluated on the potential for commercialization, translational feasibility, team expertise, and healthcare need and impact.